Workflow
FirstGene Multiple Prenatal Screen
icon
Search documents
Is it a Prudent Move to Retain MYGN Stock in Your Portfolio Now?
ZACKS· 2025-09-16 13:21
Core Insights - Myriad Genetics, Inc. (MYGN) is focusing on expanding its companion diagnostics and driving market growth through new clinical guidelines and offerings in its Oncology business, although macro pressures and competition pose significant concerns [1][10] Financial Performance - Over the past year, MYGN shares have declined by 74.5%, while the industry has seen a 13.5% decline, and the S&P 500 has gained 18.7% [2] - The company has a market capitalization of $673.6 million and a flat earnings yield that is better than the industry's -21.8% yield [2] - MYGN's earnings have surpassed estimates in three of the last four quarters, with an average surprise of 210% [2] Growth Strategies - The growth strategy for MYGN's Oncology business includes expanding companion diagnostics and introducing new offerings, such as the Precise MRD test for early cancer recurrence detection [3][10] - A study published in The Lancet Oncology demonstrated the effectiveness of the Precise MRD test in patients with oligometastatic clear-cell renal cell carcinoma [4] - The updated NCCN guidelines now include MYGN's Prolaris test for various risk levels at the time of initial biopsy [5] Product Development - MYGN is investing in innovative testing products, including the FirstGene Multiple Prenatal Screen, which is expected to expand the prenatal market by 2026 [6] - The company launched the Prequel Prenatal Screen for genetic insights as early as eight weeks into pregnancy [7] - The Precise Tumor test, which analyzes over 500 cancer-related genes, has also been introduced [8] Challenges - MYGN faces macroeconomic pressures, including inflation impacting labor costs and laboratory supply expenses, which could affect profitability [11] - Increasing competition from new players and advancements in technology may lead to price competition, potentially impacting MYGN's margins [12][13] Revenue Estimates - The Zacks Consensus Estimate for MYGN's 2025 revenues is projected at $821.7 million, indicating a 1.9% decline from the previous year [14]
Myriad Genetics Announces Early Access to the FirstGene Multiple Prenatal Screen
Globenewswire· 2025-06-03 13:00
Core Viewpoint - Myriad Genetics, Inc. has announced early access to the FirstGene Multiple Prenatal Screen, which aims to provide a comprehensive prenatal genetic risk assessment through a single blood draw without requiring paternal testing [1][2][3] Group 1: Product Overview - The FirstGene screen combines multiple testing modalities into one assay, identifying carrier status for the pregnant individual and assessing fetal risk for genetic anomalies, including chromosomal aneuploidies and pathogenic mutations in ten severe recessive conditions [2][6] - The screen also evaluates RhD compatibility between the pregnant patient and the fetus, enhancing the overall prenatal assessment process [2][6] - The assay utilizes cell-free DNA from the pregnant person, eliminating the need for a sample from the paternal reproductive partner, which is significant as only 41.5% of male partners undergo carrier screening when the pregnant person is known to be a carrier of an autosomal recessive condition [5] Group 2: Clinical Study and Validation - The FirstGene screen will be evaluated in the CONNECTOR study, which plans to enroll over 5,000 patients across multiple clinical sites, aiming to establish clinical validity and utility in a real-world setting [3] - The screen has demonstrated over 98.6% sensitivity and 99.6% specificity across variants in both the fetus and the pregnant individual, indicating its high analytical performance [3][4] Group 3: Company Strategy and Growth Opportunity - The introduction of the FirstGene screen represents a significant growth opportunity for Myriad Genetics, expanding its prenatal portfolio and enhancing the company's position in the molecular diagnostic testing market [3][8] - Myriad Genetics is committed to advancing health and well-being through innovative molecular tests that guide treatment decisions and improve patient care [8]